Just a few days after a stumble, FDA OKs 12-week dose for Eylea as Regeneron braces for Novartis attack
Well that didn’t take long.
In perhaps the shortest turnaround from an FDA rejection to an approval, Regeneron says the FDA has flagged their approval …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
